Dosage and Administration Sample Clauses

Dosage and Administration. Dosage: _________________________________________________________________________________________________________________________________ Date(s) medication to be given: ___________________________________________________________________________________________________ Times medication to be given: _____________________________________________________________________________________________________ Reasons for medication: ____________________________________________________________________________________________________________ Possible side effects: ________________________________________________________________________________________________________________ Directions for storage: ______________________________________________________________________________________________________________ Name and phone number of the prescribing health care practitioner: ____________________________________________________ Parent and Practitioner Signature Child’s Health Care Practitioner Signature: _________________________________________ Date: ______________________ I, , (parent or guardianPrint name) authorize educators to administer Medication to my child as indicated above. ___________________________________________________________________ Parent/Legal Guardian Signature _________________________ Date Individual Health Care Plan Plan was created by: Plan is maintained by: ___ Parent ___ Doctor or Licensed Practitioner ___ Program’s Health Care Consultant ___ Other: _________________________ ___ Director ___ Assistant Director ___ Child’s Educator ___ Other: ____________________________ Name of Child: Date: Any Changes to the Child’s Health Care Plan? YES (Indicate changes below) NO (updated physician/parent signatures required) Name of chronic health care condition: Description of chronic health care condition: Symptoms: Medical treatment necessary while at the program: Potential side effects of treatment: Name of educators that received training addressing the medical condition: Person who trained the educator (Child’s Health Care Practitioner, Child’s Parent programs Health Care Consultant): Name of Licensed Health Care Practitioner (please print): _______________________________________ Licensed Health Care Practitioner Authorization: _____________________________Date: ______________
AutoNDA by SimpleDocs
Dosage and Administration. The recommended daily dose in adults or elderly is 100 mg (50 mg every 12 hours). No significant increased benefit can be expected from higher daily doses. Contraindications Hypersensitivity to the active substance or to any of the excipients. Hepatic disease or baseline transaminases greater than 3 times the upper limit of normal. Patients who are pregnant or breast-feeding. In patients with impaired renal function, riluzole is not recommended for use in patients with impaired renal function, as studies at repeated doses have not been conducted in this population Side effects Asthenia, nausea, vomiting, headache, abdominal pain, dizziness, tachycardia, somnolence, oral paraesthesias, neutropenia, elevations in liver function tests. Asthenia, nausea, vomiting, headache, abdominal pain, dizziness, tachycardia, somnolence, oral paraesthesias, neutropenia, elevations in liver function tests. Drug Interactions1 There is no actual data to evaluate interactions with other drugs, however it is thought that CYP 1A2 is the principal isozyme involved in the initial oxidative metabolism of riluzole. Inhibitors of CYP 1A2 (e.g. caffeine, diclofenac, diazepam, TCAs, theophylline and quinolones) could potentially decrease the rate of riluzole elimination, while inducers of CYP 1A2 (e.g. cigarette smoke, rifampicin and omeprazole) could increase the rate of riluzole elimination.
Dosage and Administration. Neoral® capsules 10mg, 25mg, 50mg, 100mg or Oral solution 100mg/ml Maintenance dose in adult renal transplant patients: 2-6mg/kg/day (twice daily in divided doses). Dose adjusted according to trough blood-ciclosporin concentration and renal function. The concomitant intake of grapefruit juice has been reported to increase the bioavailability of ciclosporin . xxxx://xxx.xxxxxxxxx.xxx.xx Contraindication Known hypersensitivity to ciclosporin. Concomitant use of tacrolimus. Side Effects All suspected reactions (including those considered not to be serious and even where the causal link is uncertain) should be reported to the CSM. As with all immunosuppressants ciclosporin increases susceptibility to infections. Very common: renal dysfunction, hyperlipidaemia, tremor, headache, and hypertension Common: hyperuricaemia, hyperkalaemia, hypomagnesaemia, paraesthesia, anorexia, nausea, vomiting, abdominal pain, diarrhoea, gingival hyperplasia, hepatic dysfunction, hypertrichosis, muscle cramps, myalgia, fatigue Uncommon: anaemia, thrombocytopenia, signs of encephalopathy or demyelination, convulsions, confusion, disorientation, decreased responsiveness, agitation, insomnia, visual disturbances, cortical blindness, coma, paresis, cerebellar ataxia, allergic rashes, oedema, weight increase Rare: micro-angiopathic haemolytic anaemia, haemolytic uraemic syndrome, menstrual disturbances, gynaecomastia, hyperglycaemia, motor polyneuropathy, pancreatitis, muscle weakness, myopathy Very rare: optic disc oedema including papilloedema with possible visual impairment secondary to Benign Intracranial Hypertension. Drug Interactions – for detailed information refer to the SPC and Appendix 1 in BNF Drugs that decrease ciclosporin levels: Barbiturates, carbamazepine, phenytoin; rifampicin; octreotide; orlistat; hypericum perforatum (St John's Wort); ticlopidine. Drugs that increase ciclosporin levels:Macrolide antibiotics (mainly erythromycin and clarithromycin); ketoconazole, fluconazole, itraconazole; diltiazem, nicardipine, verapamil; metoclopramide; oral contraceptives; danazol; methylprednisolone (high dose); allopurinol; amiodarone; ursodeoxycholic acid; protease inhibitors. References Novartis® Pharmaceuticals UK Ltd. Summary of product characteristics, Feb 2005 xxxx://xxx.xxxxxxxxx.xxx.xx/ Ipswich Hospital. Shared care agreement for the treatment of chronic autoimmune joint & connective tissue disease, Feb 2005 BNF 51, March 2006.
Dosage and Administration. Initial Stabilisation Treatment should be started with 200mg, three times a day and may be continued for 1 week. The dosage should then be reduced to 200mg, twice daily for a further week.
Dosage and Administration dosage at two grams per day, taken as two capsules once daily, with or without food;
Dosage and Administration. Cellcept 250mg capsules, 500mg tablets or Oral suspension 1g/5ml Dose in adult renal transplant patients: 1g twice daily Contraindications Hypersensitivity to mycophenolate mofetil or mycophenolic acid. Contraindicated in breast-feeding women. For information on use in pregnancy see Summary of Product Characteristics (SPC). Side Effects All suspected reactions (including those considered not to be serious and even where the causal link is uncertain) should be reported to the CSM. xxx.xxxx.xxx.xx/Xxxxxxxxxxxxxxxxx/Xxxxxxxxxxxxxxxxxxxxxxx/xxxxx.xxx As with all immunosuppressants mycophenolate increases susceptibility to infections. The most frequent side effects seen with mycophenolate include neutropenia and gastrointestinal disturbances including diarrhoea, constipation, vomiting and indigestion. Less common side effects include gastrointestinal haemorrhage, hypertension, oedema, hyper- and hypokalaemia, hyperglycaemia, Hypophosphataemia, hypercholesterolaemia, dyspnoea, headache, dizziness, insomnia and tremor. Drug Interactions – for detailed information refer to the SPC and Appendix 1 in BNF. Aciclovir: increased plasma concentrations of aciclovir and mycophenolic acid glucuronide have been observed on concurrent administration of MMF and aciclovir.
Dosage and Administration. Recommended dose of bicalutamide is one tablet (50 mg) taken once daily.
AutoNDA by SimpleDocs
Dosage and Administration.  550mg tablet TWICE a day  Used concomitantly with high dose regular lactulose  Can be taken with or without food  Clinical benefit was established in a controlled study in which subjects were treated for 6 months. Treatment beyond 6 months should take into consideration the individual balance between benefits and risks, including those associated with progression of hepatic dysfunction1 NICE Guidance: xxxxx://xxx.xxxx.xxx.xx/guidance/ta337 Rifaximin (Targaxan®) for preventing episodes of overt hepatic encephalopathy TA 337; March 20153 “Rifaximin is recommended, within its marketing authorisation, as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in people aged 18 years or older.” Responsibilities of Consultant/ Specialist initiating treatment
Dosage and Administration. Etanercept is available as a 25mg or 50mg pre-filled syringe and a 50mg pre-filled pen for subcutaneous injection (other formulations available for paediatric use). Etanercept is administered by subcutaneous injection, either by the patient themselves or by a designated person (carer/relative). Some patients will require practice or district nurse input for administration. If this is not going to be possible please let the Rheumatology Department know as soon as possible. Contraindications and precautions for use ▪ The use of live vaccines with etanercept is contra-indicated. ▪ Patients taking Etanercept are more susceptible to serious infections (see below). ▪ Tuberculosis may be activated by etanercept. The patient will be appropriately screened by the rheumatologist as part of the initial decision-making process. ▪ Etanercept is contraindicated in moderate to severe heart failure (NYHA class III / IV) ▪ Etanercept must not be continued in patients who develop new or worsening symptoms of heart failure. ▪ The use of Etanercept in pregnant women is not recommended, and women of child-bearing potential should be advised not to get pregnant during etanercept therapy. They should use effective contraception to prevent pregnancy during therapy and for at least 3 months after discontinuation of therapy. Women must not breast feed during Etanercept therapy or for at least 3 months after Etanercept therapy is discontinued. ▪ It is also recommended that male partners receiving etanercept should use effective contraception for the time periods stated above. Side Effects (also state any specific side-effects which require the consultant to be notified) ▪ Headache, cough, nasopharyngeal pain, rash, pruritis, lower respiratory infections, viral infections (influenza, herpes), candidiasis, bacterial infections (including urinary tract infections), upper respiratory infection, injection site reaction (including pain, swelling, redness or pruritis), hepatic enzymes increased, diarrhoea, abdominal pain, stomatitis and mouth ulceration, nausea. ▪ Rare: pulmonary oedema, pancreatitis, pneumonitis. ▪ Etanercept can cause leucopenia and neutropenia. Patients who develop a new infection while undergoing treatment with Etanercept should be monitored closely. ▪ Administration of Etanercept should be discontinued if a patient develops a serious infection i.e. one that requires antibiotic therapy. Antibiotic therapy, where indicated, must be commenced promptly and only once the c...
Dosage and Administration. The recommended dose is one 50 mg tablet daily. Tablets should be taken after an overnight fast (at least 6 hours) and before the first food or drink of the day. Medicinal products and supplements (including calcium) should similarly be avoided prior to taking ibandronic acid 50 mg tablets. Fasting should be continued for at least 30 minutes after taking the tablet. Water may be taken at any time during the course of ibandronic acid 50 mg treatment. Water with a high concentration of calcium should not be used. If there is concern regarding potentially high levels of calcium in the tap water (hard water), it is advised to use bottled water with a low mineral content. The tablets should be swallowed whole with a full glass of water (180 to 240 ml) while the patient is standing or sitting in an upright position. Patients should not lie down for 60 minutes after taking ibandronic acid 50 mg Patients should not chew, suck or crush the tablet because of a potential for oropharyngeal ulceration. Water is the only drink that should be taken with ibandronic acid 50 mg Renal Impairment Mild (CrCl ≥50 and <80 mL/min). No dose adjustment is required Moderate (CrCl ≥30 and <50 mL/min) A dosage adjustment to one 50 mg tablet every second day is recommended Severe (CrCl <30 mL/min) The recommended dose is one 50 mg tablet once weekly. Hepatic impairment No dose adjustment is required Contra-indications / Special precautions Contraindication: Hypersensitivity to ibandronic acid or to any of the excipients listed Hypocalcaemia Abnormalities of the oesophagus which delay oesophageal emptying such as stricture or achalasia Inability to stand or sit upright for at least 60 minutes Pregnancy and breast-feeding - ibandronic acid should not be used in pregnancy or by women who are breast feeding. Caution:  Patients with disturbances of bone and mineral metabolism. Hypocalcaemia and other disturbances of bone and mineral metabolism should be effectively treated before starting.  Ibandronic acid therapy. Adequate intake of calcium and vitamin D is important in all patients. Patients should receive supplemental calcium and/or vitamin D if dietary intake is inadequate. Gastrointestinal irritation  Orally administered bisphosphonates may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when ibandronic acid is given to patients with active upper ga...
Time is Money Join Law Insider Premium to draft better contracts faster.